

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	4	WO 00/72874 A1	12/07/2000	Naidu		
	5	JP 09-235209	09/09/1997	Ueno, et al.		Abstract Only
Examiner Signature			Date Considered			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/590,591
				Filing Date	August 24, 2006
				First Named Inventor	Jenneke Adriana Cadec
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	0470-062554

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	6	A. A. SALAMAH et al, "Effect of some physical and chemical factors on the bactericidal activity of human lactoferrin and transferrin against Yersinia pseudotuberculosis"; MICROBIOLOGICA, vol. 18, no. 3, 1995, pages 275-281; XP002255992; Chemical Abstracts Service, Columbus, Ohio; Abstract only.	
	7	H. A. HANNA et al, "Lactoferrin (LF) and EDTA synergistic activity: An alternative antimicrobial catheter lock solution"; ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS, Vol. 42, 2002, Page 164; XP002255993; Biosciences Information Service, Philadelphia, PA, Abstract only.	
	8	M.O'D. LASSITER, "Ethylenediaminetetraacetate (EDTA): influence on the antimicrobial activity of human lactoferrin against escherichia coli and streptococcus mutans"; UNIV. MICROFILMS INT., Order No. DA9113995; From: Diss. Abstr. Int. B 1991, 51 (12, Pt. 1), 5709, 1990, pages 1-196; XP002255994; Chemical Abstracts Service, Columbus, Ohio.	
	9	D. A. DIONYSIUS, et al., "Forms of lactoferrin: Their antibacterial effect on enterotoxigenic Escherichia coli"; JOURNAL OF DAIRY SCIENCE, vol. 76, no. 9, 1993, pages 2597-2606; XP002255995; Biosciences Information Service, Philadelphia, PA, Abstract only.	
	10	H. NIKAWA, et al., "The fungicidal effect of human lactoferrin on Candida albicans and Candida krusei"; ARCHIVES OF ORAL BIOLOGY, vol. 38, no. 12, 1993, pages 1057-1063; XP002255996; Biosciences Information Service, Philadelphia, PA, Abstract only.	
	11	B. J. NONNECKE, et al., "Inhibition of mastitic bacteria by bovine milk apo lactoferrin evaluated by in-vitro micro assay of bacterial growth"; JOURNAL OF DAIRY SCIENCE, vol. 67, no. 3, 1984, pages 606-613; XP002255997; Biosciences Information Service, Philadelphia, PA, Abstract only.	
	12	C. A. BORTNER, et al., "Bactericidal effect of lactoferrin on legionella-pneumophila"; INFECTION AND IMMUNITY, vol. 51, no. 2, 1986, pages 373-377; XP002255998; Biosciences Information Service, Philadelphia, PA, Abstract only.	
	13	P. VISCA et al, "Growth and adsorption of streptococcus-mutans 6715-13 to hydroxyapatite in the presence of lactoferrin"; MEDICAL MICROBIOLOGY AND IMMUNOLOGY, vol. 178, no. 2, 1989, pages 69-80; XP002255999; Biosciences Information Service, Philadelphia, PA, Abstract only.	
	14	S. MIRZA, et al., "Bactericidal effects of lactoferrin on Streptococcus pneumoniae"; ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 101, 2001, page 142, 101 <sup>st</sup> General meeting of the American Society for Microbiology; Orlando, FL, May 20-24, 2001; XP002256000; Biosciences Information Service, Philadelphia, PA, Abstract only.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.